Actas Urol Esp (Engl Ed)

1. YAMAMOTO S, Higa K, Kurokawa K, Bamba H, et al
   Cisplatin-induced AKI risk stratification and safety of dose reduction in urothelial carcinoma patients with renal impairment.
   Actas Urol Esp (Engl Ed). 2025;49:501864.
   

   >> Share

   
   

   
   Adv Ther

2. LURAGHI P, Perrone V, Castelletti D, Losi S, et al
   Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases.
   Adv Ther. 2025 Nov 29. doi: 10.1007/s12325-025-03420.
   

   >> Share

   
   

   
   Annu Int Conf IEEE Eng Med Biol Soc

3. ABBAS S, Soomro N, Shafik R, Heer R, et al
   Attention-enabled Explainable AI for Bladder Cancer Recurrence Prediction.
   Annu Int Conf IEEE Eng Med Biol Soc. 2025;2025:1-7.
   

   >> Share

   
   
4. KANEKO S, Nosato H, Sudo K
   Development of a Free-Viewpoint Bladder Observation System for Cystoscopy.
   Annu Int Conf IEEE Eng Med Biol Soc. 2025;2025:1-4.
   

   >> Share

   
   

   
   Anticancer Res

5. KOBARI Y, Iizuka J, Kondo H, Ichioka M, et al
   Renal Function With Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in Japan.
   Anticancer Res. 2025;45:5645-5654.
   

   >> Share

   
   

   
   Arch Esp Urol

6. SHAN Y, Hou Y, Peng X, Wang N, et al
   A Rare Case of Primary Bladder Lymphoepithelial Carcinoma.
   Arch Esp Urol. 2025;78:1345-1350.
   

   >> Share

   
   
7. MANAV AN
   Case Report of Rare Metastasis of Renal Cell Carcinoma to the Bladder: A New Hypothesis and Literature Review.
   Arch Esp Urol. 2025;78:1329-1333.
   

   >> Share

   
   
8. AKAN ME, Baloglu IH, Cekmece AE, Haciosmanoglu T, et al
   Inguinoscrotal Herniation of an Orthotopic Neobladder: A Rare Case Report and Literature Review.
   Arch Esp Urol. 2025;78:1319-1322.
   

   >> Share

   
   
9. GUO J, Xue J, Yu Z, Dong J, et al
   Effect of Nutritional-Psychological Dual-Wheel-Driven Enhanced Recovery after Surgery Nursing on the Prognosis of Patients with Bladder Cancer: A Retrospective Cohort Study.
   Arch Esp Urol. 2025;78:1302-1311.
   

   >> Share

   
   
10. WANG L, Zhang F, Pan J, Shen L, et al
    Asperuloside Inhibits Bladder Cancer Cell Migration and Proliferation by Downregulating ATF6 Signalling Pathway and Inflammatory Factors.
    Arch Esp Urol. 2025;78:1277-1286.
    

    >> Share

    
    
11. HUANG Z, Cai Y, Zhong H, Zhou L, et al
    Effect of Continuity of Care on Cancer-Related Fatigue, Self-Care Ability and Fear of Recurrence in Patients with Intravesical Chemotherapy after Transurethral Resection of Bladder Tumors.
    Arch Esp Urol. 2025;78:1266-1276.
    

    >> Share

    
    
12. CHEN L, He J
    Diagnostic Values of Serum Matrix Metalloproteinase-9 and Nuclear Matrix Protein 22 for Bladder Cancer.
    Arch Esp Urol. 2025;78:1254-1260.
    

    >> Share

    
    
13. GUO H, Zhang L, Xu F, Liu P, et al
    Efficacy Evaluation of Multi-Slice Spiral CT in Patients with Muscle-Invasive Bladder Cancer after Neoadjuvant Chemotherapy with Gemcitabine and Cisplatin.
    Arch Esp Urol. 2025;78:1227-1235.
    

    >> Share

    
    

    
    Biochem Biophys Res Commun

14. QIANG Z, Ren C, Xie W, Yang Z, et al
    Baicalin inhibits bladder cancer progression by suppressing PD-L1-mediated M2 macrophage polarization via ALDH2.
    Biochem Biophys Res Commun. 2025;794:153036.
    

    >> Share

    
    

    
    Bladder (San Franc)

15. HUYNH TNA, Wei X, Arulshankar S, Lam D, et al
    (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography for bladder cancer staging: Diagnostic accuracy and prognostic implications.
    Bladder (San Franc). 2025;12:e21200066.
    

    >> Share

    
    
16. QIN C, Peng Y, Wang F, Song Y, et al
    Clinical significance of tumor location in non-muscle-invasive bladder cancer: A single-center longitudinal cohort analysis.
    Bladder (San Franc). 2025;12:e21200057.
    

    >> Share

    
    
17. LV Z, Feng Y, Guo B, Jiang B, et al
    Real-world management of T1 high-grade bladder cancer: A 14-year retrospective single-center study.
    Bladder (San Franc). 2025;12:e21200060.
    

    >> Share

    
    
18. NANDI D, Kumar SK, Hasan A, Kumar V, et al
    Diagnostic accuracy of the Vesical Imaging Reporting and Data System for muscle-invasive bladder cancer and its role in reducing repeat transurethral resection of bladder tumor: A systematic review.
    Bladder (San Franc). 2025;12:e21200065.
    

    >> Share

    
    

    
    BMC Cancer

19. LAN K, Zhang Y, Luo Y, Hong T, et al
    Global, regional, and national burdens of bladder cancer attributable to high fasting plasma glucose from 1990 to 2021, with future forecasts to 2050: a systematic analysis for the global burden of disease study 2021.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15359.
    

    >> Share

    
    
20. DU C, Wei W, Hu M, He J, et al
    Enhancing prediction accuracy for muscle invasion in bladder cancer using a dual-energy CT-based interpretable model incorporating habitat radiomics and deep learning.
    BMC Cancer. 2025;25:1842.
    

    >> Share

    
    

    
    BMC Med

21. CHEN YT, Sui J, Yang Y, Zhang H, et al
    Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancer.
    BMC Med. 2025 Dec 3. doi: 10.1186/s12916-025-04554.
    

    >> Share

    
    

    
    BMC Public Health

22. FENG W, Wang Y, Wu K, Zeng J, et al
    Global, regional, and national bladder cancer burden from 1990 to 2021 and forecasts to 2050: a systematic analysis of the global disease burden study in 2021.
    BMC Public Health. 2025 Nov 29. doi: 10.1186/s12889-025-25611.
    

    >> Share

    
    

    
    Cancer Cell Int

23. LIUFU C, Ye S, Yin C, Zhu T, et al
    Single-cell sequencing in bladder cancer: new insights from tumor cell diversity to individualized treatment strategies.
    Cancer Cell Int. 2025 Dec 3. doi: 10.1186/s12935-025-04094.
    

    >> Share

    
    

    
    Cancer Med

24. BUCHLER T, Pehalova Kusova L, Pirshtuk A, Muzik J, et al
    Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry.
    Cancer Med. 2025;14:e71427.
    

    >> Share

    
    

    
    Cancer Rep (Hoboken)

25. WEI J, Wei C, Chen J, Zhang X, et al
    A Clinically Practical Nomogram for Predicting Survival in Elderly Patients (>/= 65 Years) With Bladder Urothelial Carcinoma: A Study Based on SEER Database and External Validation.
    Cancer Rep (Hoboken). 2025;8:e70418.
    

    >> Share

    
    

    
    Cancer Sci

26. HATAYAMA T, Takemoto K, Kobatake K, Miura K, et al
    Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial-Mesenchymal Transition Pathway.
    Cancer Sci. 2025 Nov 29. doi: 10.1111/cas.70284.
    

    >> Share

    
    

    
    Clin Epidemiol

27. LIU J, Li G, Yang J, Sun B, et al
    Risk Signals of Antibody-Drug Conjugates in Bladder Cancer: A Real-World FAERS Study.
    Clin Epidemiol. 2025;17:995-1009.
    

    >> Share

    
    

    
    Cureus

28. JOHN KA, Odibo AO, Soliman AM, Abayomi M, et al
    The Future of Bladder Cancer Therapies: Integrating Hydrogel Scaffolds for Epigenetic Regulator Delivery.
    Cureus. 2025;17:e95675.
    

    >> Share

    
    

    
    Cytokine

29. HUANG Y, Gong C, Yang E, Yuan H, et al
    Natural killer cell-related gene signature predicts immune cell infiltration and improved survival in bladder cancer.
    Cytokine. 2025;197:157084.
    

    >> Share

    
    

    
    EClinicalMedicine

30. CAI L, Bai R, Cao Q, Sun W, et al
    A non-invasive MRI-based multimodal fusion deep learning model (MF-DLM) for predicting overall survival in bladder cancer: a multicentre retrospective study.
    EClinicalMedicine. 2025;90:103640.
    

    >> Share

    
    

    
    Eur J Oncol Nurs

31. LIU S, Zheng J, Sun J
    Preoperative intrinsic capacity phenotypes forecast adverse physical resilience trajectories following surgery in older bladder cancer patients.
    Eur J Oncol Nurs. 2025;80:103068.
    

    >> Share

    
    

    
    Eur Urol Focus

32. MISZCZYK M, Bilski M, Koi T, Konat-Baska K, et al
    Metastasis-directed Therapy in the Management of Urothelial Carcinoma: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2025;11:638-647.
    

    >> Share

    
    

    
    Eur Urol Open Sci

33. SHI Z, Zhang H, Yang C
    Re: Kaushik P. Kolanukuduru, Reuben Ben-David, Sarah Lidagoster, et al. Comparative Effectiveness of Bacillus Calmette-Guerin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naive Intermediate-risk Non-muscle-invasive Bladder Cance
    Eur Urol Open Sci. 2025;82:168-169.
    

    >> Share

    
    

    
    Front Endocrinol (Lausanne)

34. CHU J, Zhai J, Ma Q, Zhang Z, et al
    A case-based review of urachal carcinoma with mixed small cell neuroendocrine and adenocarcinoma components, with one new case report and analysis of nine published cases.
    Front Endocrinol (Lausanne). 2025;16:1676835.
    

    >> Share

    
    

    
    Hinyokika Kiyo

35. YANO H, Sakamoto H, Tsuruta M, Akiba D, et al
    [A Case of Bladder Squamous Cell Carcinoma Following LONG-Term-Indwelling Cystostomy].
    Hinyokika Kiyo. 2025;71:387-391.
    

    >> Share

    
    

    
    Infect Agent Cancer

36. WANG Y, Liu Z, Liu C
    Global, regional, and national burden of bladder cancer from 1990 to 2021 with projections to 2050: insights from the global burden of disease study and Mendelian randomization analysis.
    Infect Agent Cancer. 2025 Dec 2. doi: 10.1186/s13027-025-00719.
    

    >> Share

    
    

    
    J Cancer

37. DONG H, Li H, Chen S, Wang Q, et al
    Comprehensive Bioinformatics Analysis and Validation of the Mechanism of Glutamic-pyruvic Transaminase 2 in Bladder Cancer.
    J Cancer. 2025;16:4357-4370.
    

    >> Share

    
    

    
    J Immunother Cancer

38. LI K, Niu L, Zhang X, Li T, et al
    NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer.
    J Immunother Cancer. 2025;13:e013733.
    

    >> Share

    
    

    
    J Robot Surg

39. BAK R, Fabrin K, Jensen TK, Olsen KO, et al
    Comparison of the EndoGIA versus the Endowrist stapler in intracorporeal urinary diversion in robotic assisted radical cystectomy (EGIAES) - a randomized multicentre trial.
    J Robot Surg. 2025;20:51.
    

    >> Share

    
    

    
    J Transl Med

40. TAN Z
    Comments on "Unleashing the therapeutic potential of tumor-draining lymph nodes: spotlight on bladder cancer".
    J Transl Med. 2025;23:1362.
    

    >> Share

    
    

    
    JAMA Oncol

41. KHOSLA AA, Mendhiratta N, Jatwani K
    Urinary Diversion After Cystectomy for Bladder Cancer.
    JAMA Oncol. 2025 Dec 4. doi: 10.1001/jamaoncol.2025.3644.
    

    >> Share

    
    

    
    JMIR Res Protoc

42. REMMELINK MJ, Nieuwenhuijzen JA, de Bruin DM, Oddens JR, et al
    Newly Designed Optical Coherence Tomography Catheter for Optimizing Bladder Cancer Diagnosis and Treatment: Protocol for a Feasibility Study.
    JMIR Res Protoc. 2025;14:e76644.
    

    >> Share

    
    

    
    Korean J Physiol Pharmacol

43. ZHOU X, Bu Y, Xiao D, Li D, et al
    SMK-002 inhibits the growth of bladder cancer cells and increases their sensitivity to Osimertinib via enhancing epidermal growth factor receptor degradation.
    Korean J Physiol Pharmacol. 2025 Dec 4. doi: 10.4196.
    

    >> Share

    
    

    
    Mater Today Bio

44. ZHENG B, Zhang F, Wang H, Zuo W, et al
    SLC7A11-independent disulfidptosis induced by a two-pronged delivery strategy for bladder cancer chemotherapy and cisplatin-resistance reverse.
    Mater Today Bio. 2025;35:102547.
    

    >> Share

    
    

    
    Maturitas

45. LEE DY, Kim MH, Ha E, Shin S, et al
    Changes in proteinuria and the risk of urogenital cancer in Korean men.
    Maturitas. 2025;203:108754.
    

    >> Share

    
    

    
    Nat Commun

46. YAN Y, Yang S, Mach KE, Chen G, et al
    Microbial Product Cocktails for Personalized Cancer Immunotherapy.
    Nat Commun. 2025;16:10625.
    

    >> Share

    
    

    
    NPJ Precis Oncol

47. GUO X, Wang S, Ma Y, Du Y, et al
    Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study.
    NPJ Precis Oncol. 2025 Dec 3. doi: 10.1038/s41698-025-01211.
    

    >> Share

    
    

    
    Pathol Res Pract

48. ZHANG Y, Ye S, Wang S, Ding Q, et al
    SCD1 drives bladder cancer progression and trametinib sensitivity.
    Pathol Res Pract. 2025;277:156287.
    

    >> Share

    
    

    
    Pathologie (Heidelb)

49. MOLLER J, Seillier L, Furstberger A, Rose M, et al
    Evaluation of single-nucleotide variants in bladder cancer using prediction algorithms.
    Pathologie (Heidelb). 2025 Dec 3. doi: 10.1007/s00292-025-01518.
    

    >> Share

    
    

    
    Sci Adv

50. HATTON GH, James SR, Mason AS, Gawne RT, et al
    Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation.
    Sci Adv. 2025;11:eaea6124.
    

    >> Share

    
    

    
    Semin Nucl Med

51. FILIPPI L, Mass ACL, Arslan E, Alcin G, et al
    Is There a Role of FAPI Pet in Renal and Bladder Cancer?
    Semin Nucl Med. 2025 Dec 1:S0001-2998(25)00157.
    

    >> Share

    
    

    
    Urol Int

52. AYDIN O, Cinar I, Ozdemir B
    Recurrent Mullerianosis in the Bladder: A Rare Case Report That May Mimic an Adenocarcinoma.
    Urol Int. 2025;109:653-656.
    

    >> Share

    
    

    
    Zhonghua Wai Ke Za Zhi

53. WEI YY, Zhao Y, Sun SW, Liu J, et al
    [Advances in the application of patient-derived organoid models in urothelial cancer research].
    Zhonghua Wai Ke Za Zhi. 2025;63:1171-1176.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share